- MorphoSys (MOR +1.1%) raised FY20 guidance based on prelim 9M results; now expects group revenues in the range of €317 to €327M (previously: €280 to €290M) and an EBIT in the range of €10 to €20M (previously: €-15 to €+5M).
- R&D expenses are expected to remain unchanged in the range of €130 to €140M.
- Updated guidance reflects higher revenues from partnerships and collaborations and Tremfya royalties are expected to be at the upper end of guidance.
- MorphoSys (MOR +1.1%) raised FY20 guidance based on prelim 9M results; now expects group revenues in the range of €317 to €327M (previously: €280 to €290M) and an EBIT in the range of €10 to €20M (previously: €-15 to €+5M).
- R&D expenses are expected to remain unchanged in the range of €130 to €140M.
- Updated guidance reflects higher revenues from partnerships and collaborations and Tremfya royalties are expected to be at the upper end of guidance.
- https://seekingalpha.com/news/3626718-morphosys-raises-fy20-guidance
Tuesday, October 27, 2020
MorphoSys raises FY20 guidance
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.